BMT Tandem "Scientific" Meeting
Ballroom E-H (Salt Palace Convention Center)
Chairs:
Jeffrey Szer, MB BS FRACP
and
Alvaro Urbano-Ispizua, MD
Summary:
Abstracts: #2727, 2078, 2149, 2766, 2824, 1778, 2556, 2658
Clinical Outcomes of Hematopoietic Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma Transformed From Follicular Lymphoma
Baldeep Wirk, MD, University of Florida;
Linda Burns, MD, University of Minnesota;
Timothy Fenske, MD, Medical College of Wisconsin;
Zhenhuan Hu, CIBMTR;
Ginna G Laport, MD, Stanford University Medical Center;
Silvia Montoto, MD, QMUL/Barts and The London School of Medicine and Dentistry;
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center;
Wael Saber, MD, M.S., Medical College of Wisconsin/CIBMTR
Phase II Trial of High-Dose Rituximab with Thiotepa / Busulfan / Cyclophosphamide (TBC) Autologous Stem Cell Transplantation for Patients with CNS Involvement by Non-Hodgkin Lymphoma
Yi-Bin Chen, MD, Massachusetts General Hospital;
Tracy Batchelor, MD, Massachusetts General Hospital;
Ephraim Hochberg, MD, Massachusetts General Hospital;
Mark Brezina, MSN, Mass. General Hospital;
Erin Coughlin, Massachusetts General Hospital;
SooAe Jones, Massachusetts General Hospital;
Candice Del Rio, RN, Massachusetts General Hospital;
Amanda Duong, Massachusetts General Hospital;
Karen Ballen, MD, Massachusetts General Hospital;
Jeffrey Barnes, Massachusetts General Hospital;
Andrew Chi, Massachusetts General Hospital;
Jessica Driscoll, NP, Massachusetts General Hospital;
Fred Hochberg, MD, Massachusetts General Hospital;
Ann LaCasce, MD, Dana-Farber Cancer Institute;
Steven L. McAfee, MD, Massachusetts General Hospital;
Lakshmi Nayak, MD, Dana-Farber Cancer Institute;
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute
Risk Factors and Clinical Features of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation (AHCT)
Robert Frank Cornell, MD, Mazie Froedtert Willms & Sue Froedtert Cancer Fellow;
William Drobyski, MD, Medical College of Wisconsin, Hematology/Oncology;
Xiaobo Zhong, CIBMTR/Medical College of Wisconsin;
Jonathan Thompson, MD, Medical College of Wisconsin, Hematology/Oncology;
Mary M. Horowitz, MD, MS, CIBMTR/Medical College of Wisconsin;
Timothy Fenske, MD, Medical College of Wisconsin, Hematology/Oncology;
Jeanne Palmer, MD, Medical College of Wisconsin, Hematology/Oncology;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
Wael Saber, MD, M.S., CIBMTR/Medical College of Wisconsin;
Mathew Thomas, Medical College of Wisconsin, Hematology/Oncology;
Jasleen K Randhawa, MD, Medical College of Wisconsin, Hematology/Oncology;
Mei-Jie Zhang, PhD, CIBMTR/Medical College of Wisconsin;
Parameswaran N. Hari, MD, MRCP, MS, Medical College of Wisconsin, Hematology/Oncology
Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US)
Shahrukh Hashmi, MD, MPH, Mayo Clinic;
Chintan Pandya, MBBS MPH, University of Rochester;
Nandita Khera, MD, Mayo Clinic Arizona;
Morie Gertz, MD, Mayo Clinic;
Angela Dispenzieri, MD, Mayo Clinic Rochester, The William J. Von Liebig Transplant Center;
William Hogan, MBBCh, Mayo Clinic;
Mustaqeem Siddiqui, MD MBA, Mayo Clinic;
Katia Noyes, M.S. MPH. PhD, University of Rochester;
Shaji Kumar, MD, Mayo Clinic
Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience
Heather Landau, MD, TBD;
Hani Hassoun, MD, Memorial Sloan-Kettering Cancer Center;
Christina Bello, Memorial Sloan-Kettering Cancer Center;
Joanne Chou, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Raymond Comenzo, MD, Tufts Medical Center
Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America
Michael Lill, MD, Cedars Sinai Medical Center;
Luciano J. Costa, MD, PhD, Medical University of South Carolina;
Rosa F. Yeh, PharmD, Seattle Cancer Care Alliance;
Stephen Lim, MD, Cedars Sinai Medical Center;
Robert Stuart, MD, Medical University of South Carolina;
Edmund K. Waller, MD, PhD, Emory University;
Tsiporah Shore, MD, FRCPC, FACP, Weill Medical College of Cornell University and New York Presbyterian Hospital;
Michael Craig, MD, West Virginia University;
Cesar O Freytes, MD, South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio;
Thomas C. Shea, MD, University of North Carolina at Chapel Hill;
Tulio E. Rodriguez, MD, Loyola University Chicago Medical Center;
Ian W Flinn, MD, PhD, Sarah Cannon Sarah Cannon Research Institute;
Terrance Comeau, MD, BSC, New Brunswick Stem Cell Transplant Program;
Andrew M. Yeager, MD, Blood and Marrow Transplantation Program;
Michael A. Pulsipher, MD, Primary Children's Medical Center/Huntsman Cancer Institute, University of Utah School of Medicine;
Isabelle Bence-Bruckler, MD, FRCPC, The University of Ottawa, The Ottawa Hospital;
Pierre Laneuville, MD, FRCPC, Royal Victoria Hospital, McGill University Health Centre,;
Philip J. Bierman, MD, University of Nebraska Medical Center;
Andy I. Chen, MD, PhD, Oregon Health & Science;
Louie H. Yu, BS, Seattle Cancer Care Alliance;
Shiva Patil, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Yiping Sun, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Elizabeth Armstrong, MS, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Angela Smith, MS, PA, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Agnes Elekes, MD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Kazunobu Kato, MD, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
William Vaughan, MD, University of Alabama in Birmingham
Final Outcomes of Escalated Melphalan 280 MG/M2 Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (MM) : High CR+VGPR Rate Does Not Translate Into Improved Survival
Jasleen K Randhawa, MD, Medical College of Wisconsin;
Parameswaran N. Hari, MD, MRCP, MS, CIBMTR / Medical College of Wisconsin;
Donna E. Reece, MD, Ontario Cancer Institute;
David Vesole, MD, PhD, Hackensack University Medical Center
High Dose Therapy and Autologous Stem Cell Transplantation Results in Good Outcomes and Acceptable Toxicities in Elderly Patients with Non-Hodgkin's Lymphoma
Roni Tamari, MD, Memorial Sloan-Kettering Cancer Center;
Parastoo Dahi, MD, equal authorship;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Jenna Goldberg, MD, Memorial Sloan-Kettering Cancer Center;
Paul Hamlin Paul, Memorial Sloan Kettering Cancer Center;
Matthew Matasar, Memorial Sloan Kettering Cancer Center;
Jocelyn Maragulia, MS, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center;
Craig H. Moskowitz, MD, Memorial Sloan-Kettering Cancer Center;
Craig Steven Sauter, MD, Memorial Sloan-Kettering Cancer Center
![[Visit Client Website]](images/banner.gif)